Intellectual Property for Life Sciences
Life sciences is one of the most research-intensive and IP-dependent sectors in the economy. Spanning biotechnology, pharmaceuticals, diagnostics, medical devices, genomics and digital health, it is a field where discoveries take years and vast sums to develop, and where the intellectual property protecting them is often the foundation on which entire companies are built and funded. For life sciences businesses, IP strategy is not a back-office concern. It is central to survival and success.
At Panoramix IP we help life sciences companies and research organisations protect, manage and commercialise their innovation, securing patents for discoveries and technologies, navigating the regulatory-linked protections unique to the sector, safeguarding confidential data and know-how, and building the robust IP positions that investors and partners expect.
Contact us on 01522 712 433 or email info@panoramixip.co.uk to speak to our team.
Protecting Life Sciences Innovation
Life sciences innovation engages the full spectrum of IP rights, often in combination. Patents protect compounds, biologics, diagnostic methods, devices and platform technologies; trade secrets protect confidential data, processes and know-how; trade marks protect product and company brands; and copyright and design rights can protect software and device design. Because so much value rests on patents, careful drafting and prosecution, together with a clear view of the crowded prior art, are critical.
The sector’s regulatory dimension also shapes IP strategy in ways unique to life sciences. The long road to marketing approval can consume much of a patent’s term, which is why mechanisms such as Supplementary Protection Certificates (SPCs), which can extend protection for eligible regulated products, are so commercially important. We help life sciences businesses secure their core patents and assess the additional protections that can extend the commercial life of regulated products.
Funding, Collaboration and Commercialisation
In life sciences, IP and investment are inseparable. Investors and partners conduct detailed due diligence on ownership, patent strength and freedom to operate, and a weak or unclear IP position can undermine a funding round or a deal. A well-managed portfolio, by contrast, is often the single most important asset a life sciences company presents. We help businesses build and document IP positions that stand up to that scrutiny.
The sector is also intensely collaborative, with companies, universities, research institutes and clinical partners working together, and with many businesses emerging as university spinouts. Clear agreements on ownership, licensing and confidentiality are essential, as is confirming that a spinout genuinely controls its core technology. We help life sciences businesses structure their collaborations, secure their freedom to operate, and commercialise their innovation through licensing and partnerships across the jurisdictions that matter.
FAQs
Why is intellectual property so critical in life sciences?
Because life sciences products take years and large sums to develop, and their value can depend heavily on being protected from copying long enough to recoup that investment. IP, especially patents, is often the foundation on which companies are funded and built. A strong, well-managed IP position is central to both survival and success in this sector.
What are Supplementary Protection Certificates and why do they matter?
A Supplementary Protection Certificate (SPC) can extend protection for certain patented medicinal or plant protection products beyond patent expiry to compensate for time spent obtaining regulatory approval. Where available, an SPC can provide up to five additional years of protection, potentially covering some of a product’s most commercially valuable years. Given the long road to approval in life sciences, these rights can be extremely important. We help businesses assess eligibility and secure SPC protection where available.
How does IP affect our ability to raise investment?
Enormously. Investors conduct detailed due diligence on ownership, patent strength and freedom to operate, and unresolved issues can reduce valuations or derail deals. A clear, well-documented IP position is often a life sciences company’s most important asset in a raise. We help you identify and address potential gaps in advance.
We spun out of a university. Do we control our core technology?
That depends on your spinout and licensing arrangements, which vary widely. Confirming that your company owns or properly licenses its core technology is essential before building and raising investment around it, as investors will examine this closely. We help spinouts review and secure their IP position.
How do we manage freedom to operate in a crowded field?
Life sciences is densely patented, so a freedom to operate analysis can be important in identifying third-party patent rights that may affect the commercialisation of your product before you invest heavily. It allows you to manage risk early, whether by designing around, licensing or challenging a potentially blocking patent. We provide this analysis and help you determine the appropriate next steps.
Our Case Studies
Case Study: Escape Fitness
Case Study: Wow Hydrate
Case Study: The Earthshot Prize
Case Study: Cambridge Mechatronics
Case Study: The Chartered Institute of Patent Attorneys
Case Study: Lincoln City Football Club
